Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
Research onlyWeight lossSubcutaneousEvidence 2/5

HGH Fragment 176-191

Also known as: HGH Frag 176-191

A synthetic C-terminal fragment of human growth hormone claimed to stimulate adipocyte lipolysis without binding the GH receptor or raising IGF-1, though human fat-loss evidence is weak.

Read full research guideBuy / compare source

This page is a structured profile. Narrative evidence, dosing context and FAQs live on the research guide — not duplicated here as a second full article.

Illustrative subcutaneous database profile for HGH Fragment 176-191
Illustrative profileSubcutaneous
Database profileResearch only
HGH Fragment 176-191Weight loss
Drug class
Growth hormone C-terminal lipolytic fragment
Primary targets
Adipocyte lipid metabolism
Dose reference
No established human dose; research-only
Half-life
Very short (minutes); poorly characterized
Developer / origin
Ng et al. (Monash University)
Reference year
1994
Evidence score
2/5 - Weak
Evidence 2/5

Weak

Animal and isolated-tissue studies show the hGH 176-191 domain stimulates lipolysis without GH's IGF-1 effects, but there is no convincing controlled human fat-loss evidence; its optimized analog AOD-9604 failed a human obesity trial.

Mostly animal, ex vivo, cell, or indirect evidence.

Evidence basis

  • Synthetic hGH 177-191 reduced adipose mass and lipogenesis in obese mice
  • Stimulated hormone-sensitive lipase without binding the GH receptor
  • No controlled human fat-loss trial for the unmodified fragment
  • Optimized analog AOD-9604 failed human obesity development

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

HGH Fragment 176-191 guides

Read the matching guide or adjacent research pages for more context.

HGH Fragment 176-191 Peptide: Lipolysis Claims and Honest EvidenceHGH Fragment 176-191 is the C-terminal lipolytic fragment of growth hormone with animal data, but no convincing human fat-loss evidence.CagriSema: Cagrilintide + Semaglutide Trial Results, Status and LimitsCagriSema is Novo Nordisk’s investigational amylin + GLP-1 combination. Trial averages look strong, but it is not approved and is not a DIY stack of research vials.Peptides for Weight Loss: GLP-1s, Tirzepatide, Retatrutide and What WorksA broad guide to weight-loss peptides, from approved GLP-1 and dual-incretin medicines to investigational retatrutide, cagrilintide and other research compounds.GLP-1 for Weight Loss: How Well They Work, and What They CostGLP-1 weight-loss drugs produce 8–21% average body-weight reduction in trials. The honest version weighs eligibility, results, cost, side effects, and the rebound after you stop.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5
Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

DetailsGuide

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5
Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

DetailsGuide

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

DetailsGuide

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

DetailsGuide

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Read this first

PeptideStat is educational, not medical advice. Many compounds we cover are investigational or research-only and are not approved for human use. Partner links may earn us a commission without changing your price or our editorial conclusions.

Full disclosure →